Is Nonmicronized Diosmin 600 mg As Effective As Micronized Diosmin 900 mg Plus Hesperidin 100 mg on Chronic Venous Disease Symptoms? Results of a Noninferiority Study

Overview

Journal Int J Vasc Med

Publisher Wiley

Specialty Cardiology & Vascular Diseases

Date 2020 Mar 25

PMID 32206351

Citations 8

Authors

Marcio Steinbruch

Carlos Nunes

Romualdo Gama

Renato Kaufman

Gustavo Gama

Mendel Suchmacher Neto

Rafael Nigri

Natasha Cytrynbaum

Lisa Brauer Oliveira

Isabelle Bertaina

Francois Verriere

Mauro Geller

Affiliations

Soon will be listed here.

Abstract

Background: Phlebotonics have beneficial effects on some symptoms related to chronic venous disease (CVD) of the lower limbs. The most commonly used one is diosmin, available in a pure semisynthetic form or as a micronized purified flavonoid fraction. . The primary objective of this single-blind, randomized, parallel-group, prospective study was to assess the clinical noninferiority of nonmicronized diosmin 600 mg once daily (D-group) compared to micronized diosmin 900 mg plus hesperidin 100 mg once daily (D/H-group) over a 6-month treatment period. Adult patients with a symptomatic CVD of the lower limbs (C0-C3 grade; 20-60 mm on a 100 mm visual analog scale (VAS)) were included. The primary endpoint was the change (from baseline to last postbaseline value) of the intensity of the lower-limb symptoms on VAS.

Results: 114 patients (mean age, 44.4 years; women, 90.4%) were randomized in the per-protocol analysis (D-group, = 57; D/H-group, = 57; D/H-group, < 0.0001) in the D-group and -22.8 mm ( < 0.0001) in the D-group and -22.8 mm ( < 0.0001) in the D-group and -22.8 mm (.

Conclusion: Nonmicronized diosmin 600 mg was proven to have a noninferior efficacy compared to micronized diosmin 900 mg plus hesperidin 100 mg, associated with greater ease in swallowing the tablet.

Citing Articles

The Great Saphenous Vein Proximal Part: Branches, Anatomical Variations, and Their Implications for Clinical Practice and Venous Reflux Surgery.

Munteanu K, Ghirlea O, Breban-Schwarzkopf D, Danila A, Iacob R, Petrache I J Cardiovasc Dev Dis. 2024; 11(8).

PMID: 39195150 PMC: 11354398. DOI: 10.3390/jcdd11080242.

Drug Reaction with Eosinophilia and Systemic Symptoms Induced by Diosmin and Hesperidin: A Case Report.

Palakornkitti P, Rattananukrom T Clin Cosmet Investig Dermatol. 2024; 17:1127-1132.

PMID: 38770090 PMC: 11104364. DOI: 10.2147/CCID.S464672.

Anti-Inflammatory and Antioxidant Effects of Diosmetin-3--β-d-Glucuronide, the Main Metabolite of Diosmin: Evidence from Ex Vivo Human Skin Models.

Boisnic S, Branchet M, Quioc-Salomon B, Doan J, Delva C, Gendron C Molecules. 2023; 28(14).

PMID: 37513462 PMC: 10383842. DOI: 10.3390/molecules28145591.

Female Gonadal Venous Insufficiency in a Clinical Presentation Which Suggested an Acute Abdomen-A Case Report and Literature Review.

Matei S, Dumitru C, Opritoiu A, Marian L, Murariu M, Olariu S Medicina (Kaunas). 2023; 59(5).

PMID: 37241116 PMC: 10223769. DOI: 10.3390/medicina59050884.

Plant metabolite diosmin as the therapeutic agent in human diseases.

Mustafa S, Akbar M, Khan M, Sunita K, Parveen S, Pawar J Curr Res Pharmacol Drug Discov. 2022; 3:100122.

PMID: 36568270 PMC: 9780066. DOI: 10.1016/j.crphar.2022.100122.

References

Mansilha A, Sousa J . Pathophysiological Mechanisms of Chronic Venous Disease and Implications for Venoactive Drug Therapy. Int J Mol Sci. 2018; 19(6). PMC: 6032391. DOI: 10.3390/ijms19061669. View

Eklof B, Rutherford R, Bergan J, Carpentier P, Gloviczki P, Kistner R . Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg. 2004; 40(6):1248-52. DOI: 10.1016/j.jvs.2004.09.027. View

Rabe E, Guex J, Morrison N, Ramelet A, Schuller-Petrovic S, Scuderi A . Treatment of chronic venous disease with flavonoids: recommendations for treatment and further studies. Phlebology. 2013; 28(6):308-19. DOI: 10.1177/0268355512471929. View

Rehal S, Morris T, Fielding K, Carpenter J, Phillips P . Non-inferiority trials: are they inferior? A systematic review of reporting in major medical journals. BMJ Open. 2016; 6(10):e012594. PMC: 5073571. DOI: 10.1136/bmjopen-2016-012594. View

Unkauf M, Rehn D, Klinger J, de la Motte S, Grossmann K . Investigation of the efficacy of oxerutins compared to placebo in patients with chronic venous insufficiency treated with compression stockings. Arzneimittelforschung. 1996; 46(5):478-82. View

Eberhardt R, Raffetto J . Chronic venous insufficiency. Circulation. 2014; 130(4):333-46. DOI: 10.1161/CIRCULATIONAHA.113.006898. View

Rabe E, Jaeger K, Bulitta M, Pannier F . Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology. 2011; 26(4):162-8. DOI: 10.1258/phleb.2010.010051. View

Widmer L, Biland L, BARRAS J . Doxium 500 in chronic venous insufficiency: a double-blind placebo controlled multicentre study. Int Angiol. 1990; 9(2):105-10. View

Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A . Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014; (11):CD000011. PMC: 7263418. DOI: 10.1002/14651858.CD000011.pub4. View

10.

Altomare D, Giannini I . Pharmacological treatment of hemorrhoids: a narrative review. Expert Opin Pharmacother. 2013; 14(17):2343-9. DOI: 10.1517/14656566.2013.836181. View

11.

Martinez-Zapata M, Moreno R, Gich I, Urrutia G, Bonfill X . A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. Eur J Vasc Endovasc Surg. 2007; 35(3):358-65. DOI: 10.1016/j.ejvs.2007.08.012. View

12.

Baliki M, Apkarian A . Nociception, Pain, Negative Moods, and Behavior Selection. Neuron. 2015; 87(3):474-91. PMC: 4529956. DOI: 10.1016/j.neuron.2015.06.005. View

13.

Vanscheidt W, Jost V, Wolna P, W Lucker P, Muller A, Theurer C . Efficacy and safety of a Butcher's broom preparation (Ruscus aculeatus L. extract) compared to placebo in patients suffering from chronic venous insufficiency. Arzneimittelforschung. 2002; 52(4):243-50. DOI: 10.1055/s-0031-1299887. View

14.

Hahn S . Understanding noninferiority trials. Korean J Pediatr. 2012; 55(11):403-7. PMC: 3510268. DOI: 10.3345/kjp.2012.55.11.403. View

15.

Martinez-Zapata M, Vernooij R, Uriona Tuma S, Stein A, Moreno R, Vargas E . Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2016; 4:CD003229. PMC: 7173720. DOI: 10.1002/14651858.CD003229.pub3. View

16.

Santler B, Goerge T . Chronic venous insufficiency - a review of pathophysiology, diagnosis, and treatment. J Dtsch Dermatol Ges. 2017; 15(5):538-556. DOI: 10.1111/ddg.13242. View

17.

Launois R . Health-related quality-of-life scales specific for chronic venous disorders of the lower limbs. J Vasc Surg Venous Lymphat Disord. 2016; 3(2):219-27.e1-3. DOI: 10.1016/j.jvsv.2014.08.005. View

18.

Cesarone M, Incandela L, DeSanctis M, Belcaro G, Griffin M, Ippolito E . Treatment of edema and increased capillary filtration in venous hypertension with HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides): a clinical, prospective, placebo-controlled, randomized, dose-ranging trial. J Cardiovasc Pharmacol Ther. 2002; 7 Suppl 1:S21-4. DOI: 10.1177/107424840200700106. View

19.

Behar A, Nathan P, LAVIEUVILLE M, Allaert F . [Effect of veinotonyl 75 on the capillary permeability test using technetium albumin in cyclic orthostatic edemas]. Phlebologie. 1993; 46(4):721-31. View

20.

Nicolaides A, Allegra C, Bergan J, Bradbury A, Cairols M, Carpentier P . Management of chronic venous disorders of the lower limbs: guidelines according to scientific evidence. Int Angiol. 2008; 27(1):1-59. View